Cargando…
DPP4 Inhibitors and COVID-19–Holy Grail or Another Dead End?
A novel coronavirus disease, COVID-19, has emerged as a global public health issue. Clinical course of disease significantly correlates with the occurrence of some comorbidities, among them type 2 diabetes. According to recent structural studies the dipeptidyl peptidase 4, a key molecule in the path...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7850901/ https://www.ncbi.nlm.nih.gov/pubmed/33527308 http://dx.doi.org/10.1007/s00005-020-00602-5 |